Abstract 128P
Background
Biliary tract cancers are heterogeneous tumors defined by the anatomical location, intrahepatic, cholangiocarcinoma (ICC), extrahepatic (ECC), gallbladder and ampulla of Vater cancer (AVC).The outcome of treatment by location remains unclear in Latin American population, resulting in inconsistently data to enhance treatment decisions and outcome. The aim of this study is to describe the epidemiological features and prognosis of overall survival of Latin American population with biliary tract cancers.
Methods
Retrospective, observational study. Included patients treated at the National Cancer Institute between 2008 and 2022. Statistical analysis required: X2 and t test, Kaplan Meier, Log Rank and Cox Regression. Statistical significance differences were assessed when p was bilaterally <0.05.
Results
A total 786 of patients diagnosed with biliary tract cancer were included in the analysis. Patients had a median age of 61 years (24-96). Alcohol consumption and smoking were observed in 22% and 29% respectively. Regarding comorbidities, 22% had Type2DM, 27% HAS, and obesity & overweight was present in 13% and 32% respectively. Anatomical location included ICC (19%;n=151), ECC (22%;n=172), gallbladder (33%;n=259) and AVC (26%;n=204). Female were more prevalent in gallbladder and ICC (79% & 71%) (p<0.001). Median time to diagnosis was 3 months (0–120); extent of disease was observed as localized (18%;n=144), local-advanced (20%;n=158), and metastatic (60%;n=472). In metastatic patients, mean number of metastasis was 1 (1-7), being liver (66%), retroperitoneum (7%), and lung (6%) the most frequent sites. Comparing Chemotherapy and extent of disesase, 35%, 53%, and 55% patients received treatment for localized, unresectable, and metastatic (p=0.001). An OS analysis was conducted considering location, ICC patients showed a median-OS of 9months, ECC a median-OS of 12months, gallbladder a median-OS of 1months and AVC did not reach median-OS (p<0.001).
Conclusions
Prognosis and outcome for patients with biliary tract cancer differ depending on the anatomical subsite. This is one of the main studies describing epidemiological features, and outcome in Latin American patients with biliary tract.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17